Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526838 · ClinicalTrials.gov registry record · Phase 1
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00526838 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 84 participants.
The verdict
NCT00526838, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
Interventions
- DRUG XL228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00526838
The ClinicalTrials.gov registry entry for NCT00526838 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL228 is the first listed.
NCT00526838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00526838 about?
NCT00526838 is a clinical study titled "Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies". The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
What is the current status of trial NCT00526838?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2007-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00526838?
The interventions under investigation include: XL228 (DRUG).
Who is sponsoring clinical trial NCT00526838?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.